According to GlobalData’s medical device pipeline database, six Polymerase Chain Reaction (PCR) Systems devices are in various stages of development globally. GlobalData’s report Polymerase Chain Reaction (PCR) Systems provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Smarter leaders trust GlobalData
Of these devices, six are in active development, while the remaining one is in an inactive stage of development. There are one products in the early stages of development, and the remaining five are in the late stages of development.
In Vitro Diagnostics (IVD) include reagents, instruments and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. Polymerase chain reaction (PCR) is a revolutionary method used to analyze and amplify short DNA (or RNA) sequences in a sample with small quantities of RNA or DNA. PCR amplifies the selected sequence of DNA segment producing millions of copies within a few hours. Polymerase Chain Reaction (PCR) Systems are instruments used to perform nucleic acid amplification, typically in support of investigations concerning the diagnosis or prognosis of cancer or infectious disease. Tracked here is the equipment only, and not accessories and/or additional costs associated with PCR System installation. It includes the sub-segments Semi Automated qPCR Systems, Automated qPCR Systems, and Digital PCR Systems. The Polymerase chain reaction (PCR) is a method used to amplify and analyze short DNA (or RNA) sequences in a sample with small quantities of RNA or DNA, through repeated heating and cooling of nucleic acids, combined with recombinant enzymes, to mimic the natural process used in cells to repair DNA. PCR amplifies the selected sequence of DNA segment producing millions of copies within a few hours. Quantitative PCR (qPCR) is a modification of the technique that allows measurement of the amplified RNA or DNA. The Polymerase Chain Reaction (PCR) Systems tracks the essential equipment only, and not accessories and/or additional costs associated with PCR System installation. It includes the sub-segments Semi Automated qPCR Systems, Automated qPCR Systems, and Digital PCR Systems.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Polymerase Chain Reaction (PCR) Systems pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Polymerase Chain Reaction (PCR) Systems devices. Overall, most of these Polymerase Chain Reaction (PCR) Systems pipeline devices are being developed by private entities.
Key players involved in the active development of Polymerase Chain Reaction (PCR) Systems include Roche Diagnostics International, Stilla Technologies, Bio-Rad Laboratories and Qiagen.
For a complete picture of the developmental pipeline for Polymerase Chain Reaction (PCR) Systems devices, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
